Related Experiment Videos

Chemotherapy of human tumors in T-lymphocyte-deficient mice

Cancer Treatment Reports
|May 1, 1977
PubMed

Insights

This study shows that T-lymphocyte-deprived mice can grow human carcinomas. Hexamethylmelamine demonstrated significant efficacy against these tumors, suggesting its potential in cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Human carcinomas (lung, ovarian, colonic, renal) were xenografted into T-lymphocyte-deprived mice.
  • Tumor growth and karyotype stability were maintained across transplant generations.

Purpose of the Study:

  • To evaluate the efficacy of chemotherapy on human carcinomas in an immunocompromised mouse model.
  • To assess the role of hexamethylmelamine and plasma carcinoembryonic antigen (CEA) levels in drug response.

Main Methods:

  • Xenotransplantation of human carcinomas into T-lymphocyte-deprived mice.
  • Administration of chemotherapy, including hexamethylmelamine.
  • Monitoring tumor growth and measuring plasma carcinoembryonic antigen (CEA) levels.

Main Results:

  • Carcinomas grew slowly but maintained human karyotypes.
  • Hexamethylmelamine induced complete regression in lung and renal carcinomas and inhibited ovarian carcinoma growth.
  • Plasma CEA levels were valuable in assessing drug efficacy.

Conclusions:

  • T-lymphocyte-deprived mice serve as a viable model for studying human carcinoma xenografts.
  • Hexamethylmelamine exhibits potent anti-tumor activity against specific human carcinomas in this model.
  • Plasma CEA is a useful biomarker for monitoring treatment response in these models.

Related Concept Videos